Abemaciclib and Letrozole to Treat Endometrial Cancer

Active:	No
Cancer Type:	Unknown Primary Uterine Cancer	NCT ID:	NCT04393285
Trial Phases:	Phase II	Protocol IDs:	GOG-3039 (primary) NCI-2020-08167
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Gynecologic Oncology Group
NCI Full Details:	http://clinicaltrials.gov/show/NCT04393285

Summary

This is a phase II single arm trial to determine the percentage of patients without
evidence of disease progression on abemaciclib and letrozole in advanced stage,
persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will
continue until either unacceptable toxicity, progression of disease, or
investigator/patient request for withdrawal.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.